Pro-inflammatory cytokines and psychotherapy in depression: Results from a randomized clinical trial

Silva, Giovanna Del Grande da; Wiener, Carolina David; Barbosa, Luana Porto; Araújo, Jaciana Marlova Gonçalves; Molina, Mariane Lopez; Martin, Pedro San; Oses, Jean Pierre; Jansen, Karen; Souza, Luciano Dias de Mattos; Silva, Ricardo Azevedo da

doi:10.1016/j.jpsychires.2016.01.008

Cited by 54 publications

(25 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…What is more, studies conducted by Dahl et al [2016] and Del Grande da Silva et al [2016] demonstrated cytokine levels normalization after psychotherapy. Future trials should be conducted with the use of placebo standard to allow exploration of this query.…”

Section: Accepted Manuscriptmentioning

confidence: 93%

Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis

Więdłocha

Marcinowicz

Krupa

et al. 2018

Progress in Neuro-Psychopharmacology and Biological Psychiatry

183

106

View full text Add to dashboard Cite

Section: Accepted Manuscriptmentioning

confidence: 93%

Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis

Więdłocha

Marcinowicz

Krupa

et al. 2018

Progress in Neuro-Psychopharmacology and Biological Psychiatry

183

106

View full text Add to dashboard Cite

“…Psychological interventions (such as cognitive behavior therapy, mindfulness-based cognitive therapy, cognitive behavioral analysis system of psychotherapy and interpersonal psychotherapy) is an effective treatment for MDD. In a randomized clinical trial in MDD patients, results showed that serum IL-6 levels, as well as depression severity, significantly decreased after 16 sessions of supportive-expressive dynamic psychotherapy [123]. It was found that after individual mindfulness training, the salivary IL-6 levels had decreased, which was maintained for 3 months, in a study testing the application of brief mindfulness intervention in young women with depressive symptomatology [124].…”

Section: Psychological Interventionsmentioning

confidence: 99%

Role of Interleukin-6 in Depressive Disorder

Ting

Yang

Tsai

2020

IJMS

248

152

View full text Add to dashboard Cite

Major depressive disorder (MDD), which is a leading psychiatric illness across the world, severely affects quality of life and causes an increased incidence of suicide. Evidence from animal as well as clinical studies have indicated that increased peripheral or central cytokine interleukin-6 (IL-6) levels play an important role in stress reaction and depressive disorder, especially physical disorders comorbid with depression. Increased release of IL-6 in MDD has been found to be a factor associated with MDD prognosis and therapeutic response, and may affect a wide range of depressive symptomatology. However, study results of the IL6 genetic effects in MDD are controversial. Increased IL-6 activity may cause depression through activation of hypothalamic-pituitary-adrenal axis or influence of the neurotransmitter metabolism. The important role of neuroinflammation in MDD pathogenesis has created a new perspective that the combining of blood IL-6 and other depression-related cytokine levels may help to classify MDD biological subtypes, which may allow physicians to identify the optimal treatment for MDD patients. To modulate the IL-6 activity by IL-6-related agents, current antidepressive agents, herb medication, pre-/probiotics or non-pharmacological interventions may hold great promise for the MDD patients with inflammatory features.

show abstract

“…For instance, cognitive behavioral therapy (CBT) has shown promise in reducing dysphoria/hopelessness in depressed patients [84, 85]. Brief supportive-expressive psychodynamic psychotherapy has also been shown to lower the serum levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin 6 (IL-6) [86], that might play a mediating role after T. gondii reactivation in chronically infected individuals, and have been implicated in the metabolism of neurotransmitters, activation of neuroendocrine pathways, altered neuroplasticity [87] and behavioral manifestations seen in depressed individuals [88]. In T. gondii -seropositive patients with elevated markers of inflammation, clinical trials on anti-inflammatory drugs such as celecoxib [89], infliximab [90], or other cytokine inhibitors and anti-cytokine monoclonal antibodies [91], may lead to novel interventions for refractory or persistently suicidal depression.…”

Section: Discussionmentioning

confidence: 99%

Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study

et al. 2017

View full text Add to dashboard Cite

AbstractToxoplasma gondii (T. gondii) IgG seropositivity and serointensity have been previously associated with suicidal self-directed violence (SSDV). Although associations with unipolar depression have also been investigated, the results have been inconsistent, possibly as a consequence of high heterogeneity. We have now studied this association in a more homogeneous population, [that is (i.e.) Old Order Amish (OOA)] with previously reported high T. gondii seroprevalence. In 306 OOA with a mean age of 46.1±16.7 years, including 191 (62.4%) women in the Amish Wellness Study, we obtained both T. gondii IgG titers (by enzyme-linked immunosorbent assay [ELISA]), and depression screening questionnaires (Patient Health Questionnaire [PHQ-9] [n=280] and PHQ-2 [n=26]). Associations between T. gondii IgG and dysphoria/hopelessness and anhedonia scores on depression screening questionnaires were analyzed using multivariable linear methods with adjustment for age and sex. Serointensity was associated with both current dysphoria/hopelessness (p=0.045) and current combined anhedonia and dysphoria/hopelessness (p=0.043), while associations with simple anhedonia and past/lifelong (rather than current) phenotypes were not significant. These results indicate the need for larger longitudinal studies to corroborate the association between dysphoria/hopelessness and T. gondii IgG-titers. Current hopelessness is a known risk factor for SSDV which responds particularly well to cognitive behavioral therapy, and may be a focused treatment target for T. gondii-positive individuals at high-risk for SSDV.

show abstract

Pro-inflammatory cytokines and psychotherapy in depression: Results from a randomized clinical trial

Cited by 54 publications

References 48 publications

Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis

Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis

Role of Interleukin-6 in Depressive Disorder

Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study

Contact Info

Product

Resources

About